Can You Take Apixaban and Rifampin Together?

No. Apixaban and rifampin should not be taken together. Rifampin significantly reduces the concentration of apixaban in your bloodstream, which decreases its ability to prevent blood clots and increases your risk of stroke and thromboembolic events. FDA drug labeling for apixaban (brand name Eliquis) recommends avoiding this combination entirely.

What the Source Says

The interaction record from FDA apixaban labeling classifies this drug pair as contraindicated—meaning the combination should be avoided under normal circumstances. The documented description states that rifampin is a combined P-glycoprotein and strong CYP3A4 inducer that decreases apixaban exposure and increases risk of stroke and thromboembolic events.

This classification reflects a high-severity interaction with documented clinical consequences. The source record specifies both the pharmacological mechanism (CYP3A4 and P-glycoprotein induction) and the clinical outcome (reduced efficacy leading to increased clot and stroke risk). The guidance is direct: concomitant use should be avoided.

How to Understand This Interaction

To understand why this interaction matters, it helps to know how apixaban works and how rifampin interferes with it.

How Apixaban Reaches and Stays in Your Body

Apixaban is an oral anticoagulant—a blood-thinner medication that works by blocking a clotting protein in your blood. After you swallow an apixaban tablet, your digestive system absorbs it, and it enters your bloodstream. To be effective, apixaban needs to maintain a certain concentration (level) in your blood at all times.

Your body eliminates apixaban through two main pathways. The first is a liver enzyme called cytochrome P450 3A4 (CYP3A4). The second is a transport protein called P-glycoprotein, which actively pumps apixaban molecules out of cells and into the liver and kidneys for elimination. Both of these systems work together to keep apixaban moving through your body and out of it.

What Rifampin Does

Rifampin is an antibiotic used primarily to treat tuberculosis and other mycobacterial infections. It is a particularly potent inducer of both CYP3A4 and P-glycoprotein. "Induction" means that rifampin causes your liver and cells to produce more of these enzymes and transport proteins.

When rifampin induces CYP3A4 and P-glycoprotein, your body dramatically accelerates the breakdown and removal of apixaban. The result is that apixaban blood levels fall—sometimes substantially—even though you are taking the same dose.

The Clinical Consequence

Lower apixaban levels mean less anticoagulant effect. If you are taking apixaban to prevent a stroke caused by atrial fibrillation, to treat a blood clot (deep vein thrombosis or pulmonary embolism), or to prevent clots after orthopedic surgery, a significant drop in apixaban concentration undermines that protection. The documented risk is an increased likelihood of thromboembolism—meaning clots that can travel and cause stroke, heart attack, or pulmonary embolism.

Why Simple Dose Adjustment May Not Work

It might seem logical to simply increase the apixaban dose to compensate for faster elimination. However, the FDA labeling recommendation is to avoid concomitant use altogether, not to adjust the dose. This reflects the unpredictability of the interaction and the potential difficulty in achieving reliable anticoagulation when both drugs are present. The induction effect of rifampin can vary between individuals, making it hard to predict the exact degree of apixaban reduction in any given patient.

The Documented Mechanism in Context

The source record identifies the mechanism as "CYP3A4 and P-gp induction." This is a well-established pharmacological fact about rifampin's behavior.

CYP3A4 Induction

CYP3A4 is the most abundant drug-metabolizing enzyme in the human liver. Rifampin is a known and potent inducer of CYP3A4—meaning it increases the expression and activity of this enzyme. When CYP3A4 activity increases, the rate at which apixaban is metabolized speeds up. Many anticoagulants, antiretrovirals, immunosuppressants, and other drugs depend on CYP3A4 for elimination, so rifampin's induction effect is clinically significant across multiple drug classes.

P-Glycoprotein Induction

P-glycoprotein (also called MDR1 or ABCB1) is an efflux transporter—a protein that pumps molecules out of cells. Apixaban is a substrate of P-glycoprotein, meaning P-glycoprotein helps transport it out of the intestinal lining (where it is absorbed) and out of other tissues for elimination. Rifampin induces P-glycoprotein expression, causing more transporter protein to be present. This amplifies the removal of apixaban from your body through an additional pathway beyond liver metabolism.

The Combined Effect

The interaction is particularly potent because rifampin operates on both pathways simultaneously. You are not just speeding up one elimination route; you are accelerating two independent systems that remove apixaban. Clinical data and pharmacokinetic studies have documented that this combination results in substantial reductions in apixaban exposure—the area under the blood-concentration curve (AUC)—compared to apixaban alone.

Who Should Pay Particular Attention

Anyone prescribed both apixaban and rifampin faces this interaction. However, the clinical stakes are highest for patients in whom anticoagulation failure carries the greatest immediate risk:

• Patients with atrial fibrillation taking apixaban for stroke prevention: loss of anticoagulant effect directly increases stroke risk.
• Patients being treated for acute venous thromboembolism (deep vein thrombosis or pulmonary embolism): reduced apixaban levels can allow clot progression or recurrence.
• Patients with mechanical heart valves or other high-risk thrombotic conditions: any reduction in anticoagulant efficacy is dangerous.
• Older adults and those with renal impairment: these populations may have less physiologic reserve and may be more sensitive to fluctuations in anticoagulant levels.

That said, the FDA recommendation to avoid concomitant use is not limited to high-risk subgroups—it is a general contraindication meant to protect any patient taking the combination.

Hypothetical Example 1: A Patient With TB and Atrial Fibrillation

Consider a hypothetical patient diagnosed with active tuberculosis who also has atrial fibrillation and was prescribed apixaban for stroke prevention. If a physician were to attempt treating the TB with rifampin while continuing apixaban, the rifampin would induce CYP3A4 and P-glycoprotein, causing apixaban blood levels to drop substantially. The patient might continue taking both medications as prescribed, believing they are protected from stroke, but the apixaban concentration would be insufficient for anticoagulation. The patient's stroke risk would rise—potentially to a level comparable to, or exceeding, the risk without any anticoagulant therapy.

This scenario illustrates why the interaction is classified as contraindicated rather than merely "caution advised"—the consequence is not a minor side effect adjustment, but a potential failure of life-saving therapy.

Hypothetical Example 2: Recognizing the Interaction Early

In a better scenario, a patient's pharmacist or physician recognizes that rifampin is being considered or started and catches the potential apixaban interaction before both drugs are given together. At that point, alternative antibiotics for TB (some of which do not induce CYP3A4 and P-glycoprotein) or alternative anticoagulants (some of which do not depend on these pathways) can be considered. This illustrates the importance of comprehensive medication review and why discussing your full medication list with your healthcare team before starting a new drug is essential.

What to Discuss With a Pharmacist or Physician

If you are currently taking apixaban and rifampin has been recommended or prescribed to you, or if you are on both drugs, bring this to your healthcare provider's immediate attention. Here are key conversation starters:

• "I am on apixaban for [my condition]. If I need to take rifampin for TB or another infection, are there alternative antibiotics that would not interfere with my blood thinner?" Rifampin is not the only TB antibiotic available; others may not induce CYP3A4 or P-glycoprotein, or may do so to a lesser degree.
• "Are there alternative anticoagulants that would work better if I need rifampin?" Different anticoagulants have different metabolic pathways. Your provider may switch you to a drug that is not affected by rifampin-induced induction.
• "Should we change my apixaban dose if I have to take rifampin?" The FDA labeling says to avoid the combination rather than adjust the dose, but your provider may discuss the specific risks and benefits in your clinical situation and whether any dose adjustment is feasible—though this would be an exception to the standard recommendation.
• "How long after stopping rifampin would my apixaban dose be reliable again?" Induction effects take time to reverse. Even after you stop rifampin, it can take days to weeks for CYP3A4 and P-glycoprotein activity to return to baseline, so blood levels of apixaban would remain low during that transition.
• "What signs should I watch for that suggest my blood thinner is not working?" Ask your provider about symptoms of clot formation (leg swelling, chest pain, shortness of breath, sudden weakness or speech difficulty) and when to seek emergency care.

Do not stop or change your apixaban dose on your own. These are conversations to have with your prescribing physician and pharmacist, who know your full medical history and can make an informed decision about the best alternative.

Key Takeaways

• Apixaban and rifampin are contraindicated and should not be taken together, according to FDA drug labeling.
• Rifampin is a potent inducer of CYP3A4 and P-glycoprotein, two pathways that eliminate apixaban from your body. This induction significantly reduces apixaban blood levels and its anticoagulant effect.
• Lower apixaban levels increase your risk of stroke and blood clots, undermining the reason you are taking the medication in the first place.
• There are alternative antibiotics for tuberculosis and other conditions that do not induce these metabolic pathways, and your provider should explore these as first-line options if you need an antibiotic while on apixaban.
• Discuss this interaction with your pharmacist and physician immediately if both drugs have been prescribed to you. Do not adjust or stop either medication without professional guidance.

Sources

• DailyMed (FDA Drug Labeling Database) — Search for apixaban to access the current FDA-approved prescribing information and contraindications.
• RxNorm (NIH/NLM) — A comprehensive source for drug nomenclature, ingredients, and cross-references.
• Open FDA — A public database of FDA drug approvals, labeling changes, and adverse event reports.
• PubMed (NIH National Library of Medicine) — Search for peer-reviewed literature on apixaban pharmacokinetics, CYP3A4 induction, and P-glycoprotein transporters for in-depth scientific context.

To verify your full medication list and check for interactions beyond this pair, visit checkdruginteractions.com. Enter all of your current medications—including over-the-counter drugs, supplements, and herbal products—to identify any documented interactions. Then confirm any medication decisions with your pharmacist or physician. If you are currently taking both apixaban and rifampin, contact your healthcare provider or pharmacist today to discuss safer alternatives.